295
Participants
Start Date
November 9, 2020
Primary Completion Date
March 31, 2021
Study Completion Date
March 31, 2021
Camostat Mesilate
Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
Placebo
Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.
Cary Research Group (Site 111), Cary
Onsite Solutions (Site 118), Charlotte
Visionaries Clinical Research, LLC (Site 121), Atlanta
Reliable Clinical Research, LLC (Site 100), Hialeah
Invictus Clinical Research Group, LLC (Site 101), Pompano Beach
A+ Research (Site 112), Miami
NextPhase Research Alliance at CANO HEALTH (Site 107), Miami
Ezy Medical Research (Site 106), Miami
Eminat LLC (Site 117), Plantation
Clinical Research of Brandon, LLC (Site 123), Brandon
Synergy Healthcare, LLC (Site 124), Bradenton
Toledo Institute of Clinical Research, Inc.(Site 105), Toledo
STAT Research (Site 109), Springboro
Oakland Medical Research Center (Site 108), Troy
Cedar Crosse Research Center (Site 122), Chicago
Next Innovative Clinical Research (Site 115), Houston
Rio Grand Valley Clinical Research Institute (Site 120), Pharr
Advanced Medical Trials (Site 104), Georgetown
Family Care Research (Site 114), Boise
Palmtree Clinical Research, Inc. (Site 125), Palm Springs
Massachusetts General Hospital (Site 110), Boston
Sagent Pharmaceuticals Inc.
INDUSTRY